CCHR Urges Overhaul of the FDA, Charging Approval of Electroshock Device Creates Harm


In December 2018, the FDA reduced the risk classification of the electroshock device so that it could be more broadly marketed and used for the treatment of mental disorders. The decision has prompted CCHR to call upon the GAO to investigate the agency.

In December 2018, the FDA reduced the risk classification of the electroshock device so that it could be more broadly marketed and used for the treatment of mental disorders. The decision has prompted CCHR to call upon the GAO to investigate the agency.

The group charges that the FDA’s duty to protect consumers is compromised by vested interests that insist ECT remains on the market despite dangers to patients.

The FDA’s Final Order on the ECT device in December 2018 put the draconian, brain damaging device into the same risk classification as contact lens, mercury thermometers, condoms and pregnancy tests.”

— Citizens Commission on Human Rights

CLEARWATER, FLORIDA, UNITED STATES, October 21, 2019 /EINPresswire.com/ — Summing up a five-part series of articles exposing the dangers of electroshock treatment (ECT) on its public information blog, TruthAboutECT, mental health watchdog, Citizens Commission on Human Rights International (CCHR) calls for an overhaul of the Food and Drug Administration (FDA). CCHR says the FDA’s handling of the ECT device, allowing it to stay on the market without clinical trials proving safety and efficacy, is another example of the agency’s long history of approving and allowing dangerous products. CCHR is urging the U.S. General Accountability Office to investigate the agency’s approval of the ECT device, putting industry interests before patient protection.

A Propublica investigation in 2018 found pharmaceutical companies underwrite three-fourths of the FDA’s budget for scientific reviews. The agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits. [1] Drugs used to treat “mental illness” and those that went through an accelerated approval process have a higher number of adverse events, according to a Journal of the American Medical Association (JAMA) study. [2] In November 2018, an Associated Press analysis of FDA data showed that since 2012, tens of thousands of injury and death reports have been filed in connection with devices that were cleared through a streamlined pathway that minimizes clinical trial testing. [3]

There are no clinical trials proving the ECT device safe and effective. Nor does the FDA monitor the use of ECT or have accurate information about electroshock deaths. Texas is the only state mandated to report a death within 14 days of ECT being administered. Between 1993 and 1998 alone there were 30 deaths. Based on an average number of Texas ECT deaths in 2013, 2014 and 2016, nationally about 70 Americans undergoing ECT may die every year.

The Texas suicide rate for patients shortly following ECT was also 13 times greater than the state suicide rate in a year. [4]

Psychiatrists and the FDA downplay deaths, attributing them to other diverse reasons rather than admit to the damage 460 volts of electricity does to the brain and body.

Jan Eastgate, president of CCHR International says industry funding may play a strong part in this: “With a heavy reliance upon industry funds, FDA cannot afford to alienate its funding sources.” About 45%, or $2.4 billion of the FDA’s budget, is paid for by industry user fees. [5]

In 2017, Pharma paid 75%—or $905 million—of the agency’s scientific review budgets for branded and generic drugs, compared to 27% in 1993. “The virginity was lost in ’92,” said Dr. Jerry Avorn, a professor at Harvard Medical School. “Once you have that paying relationship, it creates a dynamic that’s not a healthy one.” [6]
Medical devices and Radiological Health regulatory activities, under which the ECT devices fall, accounted for another 10% of FDA’s budget ($570 million); 33% of these activities are paid for by industry user fees ($188.1 million). [7]

As far as protecting the public, the FDA’s history of neglect is well documented and legendary, Eastgate adds.

The FDA has only banned two medical devices since 1976—one that implanted artificial hair into the scalp and powdered surgical gloves. [8]

• The hair implant device was banned in 1983 because it failed to stimulate hair growth, conceal baldness as advertised and caused infections and injury where implanted. [9]
• The powdered gloves could cause severe airway inflammation and hypersensitivity reactions. [10]

Compare these to the serious adverse effects of the ECT that include manic or a worsening of the “psychiatric” symptoms, pain/somatic discomfort (including headache, muscle soreness, and nausea); skin burns; physical trauma (including fractures, contusions, injury from falls, dental and oral injury); prolonged or delayed onset seizures; pulmonary complications; cardiac arrhythmias, heart attack, high or low blood pressure, and stroke; permanent memory loss and death. [11]

From December 1978 through February 1981, FDA received 166 complaints about the hair fibers. [12] It received approximately 100 public comments on powdered gloves. Yet in 2009, the agency received more than 3,000 comments on the electroshock device, of which 79% opposed it—14 times greater than for those in favor of it. Yet the FDA’s Final Order on the ECT device in December 2018 put the draconian, brain damaging device into the same risk classification as contact lens, mercury thermometers, condoms and pregnancy tests, CCHR reports. [13]

The group charges that the FDA’s duty to protect consumers from health hazards is compromised by “who pays” and by vested interests that insist that ECT, described as torture, remains on the market, despite the imminent danger to patients.

It points to Chief Counsel, Brigadier General Telford Taylor in his opening statement to the Nuremberg Nazi Medical Trials following WWII: “To kill, to maim, and to torture is criminal under all modern systems of law….It is far more important [to the unfortunate victims of Nazi atrocities] that these incredible events be established by clear and public proof…and that this court, as the agent of the United States and as the voice of humanity, stamp these acts, and the ideas which engendered them, as barbarous and criminal.” [14] (See previous article on ECT used by the Nazis)

Eastgate says: “The FDA is an agent for the U.S. that needs an overhaul. Electroshock is an atrocity that should not remain on the market.”

Over 95,000 people have signed CCHR’s online petition to ban electroshock. More are encouraged to sign this and to report any incident of ECT damage to CCHR.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. L. Ron Hubbard, founder of Scientology, first brought psychiatric imprisonment to wide public notice: “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health,’” he wrote in March 1969. For more information visit www.cchrflorida.org

Sources:

[1] Caroline Chen, “FDA Repays Industry by Rushing Risky Drugs to Market,” Propublica, 26 June 2018, https://www.propublica.org/article/fda-repays-industry-by-rushing-risky-drugs-to-market
[2] Jen Christensen, “Nearly a third of FDA-approved drugs had problems, study finds,” CNN, 9 May 2017, https://www.cnn.com/2017/05/09/health/fda-approval-drug-events-study/index.html
[3] Matthew Parrone, “At FDA, a new goal, then a push for speedy device reviews,” AP, 27 Nov. 2018, https://www.boston.com/news/politics/2018/11/27/us-goal-to-be-first-on-devices-worries-former-regulators
[4] “Texas Injury Data Brief,” Texas Department of State Health Services (DSHS), https://www.dshs.texas.gov/injury/EPI/Suicide2016Update.pdf; “Electroconvulsive Therapy Annual Report 2014,” Department of State Health Services, March 2015, https://www.dshs.texas.gov/legislative/2015/ECT-Annual-Report-2014.pdf
[5] https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance
[6] Op cit., Caroline Chen
[7] https://www.fda.gov/about-fda/fda-basics/fact-sheet-fda-glance
[8] https://www.fda.gov/MedicalDevices/Safety/MedicalDeviceBans/default.htm.
[9] https://www.upi.com/Archives/1983/06/03/Ban-hair-fiber-and-synthetic-hair-implants/5598423460800/.
[10] http://www.mocarehealth.com/news.php?id=46.
[11] https://www.federalregister.gov/documents/2018/12/26/2018-27809/neurological-devices-reclassification-of-electroconvulsive-therapy-devices-effective-date-of
[12] Op. cit., UPI.com
[13] https://www.innovatum.com/2014/12/understanding-difference-class-class-ii-medical-devices/
[14] Evelyne Shuster, “Medical Ethics at Nuremberg: The Nazi Doctors and the Hippocratic Oath,” prepared for the Annual Ethics Symposium Fifty Years After the Nuremberg Medical Trail (Are) Forming Institutional Review Boards, Philadelphia Veteran Affairs Medical Center, 24 May 1996

Diane Stein
Citizens Commission on Human Rights of Florida
+1 727-422-8820
email us here

Electroconvulsive “Therapy” —The Facts about ECT #BanECT


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.



Source

Research Deliver Insight into HbA1c Testing Device Market 2019-2025


Wise.Guy12

Wise.Guy.

Wiseguyreports.Com Adds “HbA1c Testing Device 2019-2025 Global Market Survey Industry Key Players” To Its Research Database

PUNE, MAHARASTRA, INDIA, October 9, 2019 /EINPresswire.com/ — Summary

Wiseguyreports.Com Adds “HbA1c Testing Device 2019-2025 Global Market Survey Industry Key Players – Abbott Laboratories, Roche, Siemens, Tosoh, Danaher Corporation” To Its Research Database

HbA1c Testing Device Market 2019-2025

Description: –

This report exclusively compiles all the fundamental dynamics that sheds light on the HbA1c Testing Device market for a comprehensive view of the market. Market potentials, as well as pitfalls, are discussed at length along with essential macro and micro-economic trends, which can affect the market growth. Prevalent market trends and factors that are likely to provide opportunities to the market have also been taken into consideration while making projections. Forecasts pertaining to the overall market size, CAGR, regional market size have been provided in the report. Historical data analysis provided in the report helps in determining the future trajectory of the market. All the activities in the market are analyzed thoroughly to develop the core of the report.

Free Sample Request @ https://www.wiseguyreports.com/sample-request/4073862-global-hba1c-testing-device-market-report-2019-market

The major manufacturers covered in this report

Abbott Laboratories
Roche
Siemens
Tosoh
Danaher Corporation
Bio-Rad Laboratories

………….

Major market players have been identified in the report, and a strategic focus has been placed on emerging players in the market. Key competencies of each player, efforts made by them, new product launches, innovation, and the strategies adopted by each player have been included in the report which helps to deduce the level of competition in the market. Moreover, the geographical presence of each player and their respective market shares have been included in the report.

The HbA1c Testing Device market has been branched down into various segments to promote a thorough understanding of the overall market structure. Emphasis has been placed on growing segments of the market, and growth rate and market share of each segment have been provided in the report. Market attractiveness of each segment has also been discussed in the report.

For Detailed Report Visit @ https://www.wiseguyreports.com/reports/4073862-global-hba1c-testing-device-market-report-2019-market

Major Key Points in Table of Content:

Continued……

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
08411985042
email us here


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.



Source